Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling
- PMID: 10482961
- DOI: 10.1038/sj.ejhg.5200367
Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling
Abstract
Glycogen storage disease type II (GSD H) is an autosomal recessive myopathy. Early and late-onset phenotypes are distinguished - infantile, juvenile and adult. Three mutations in the acid alpha-glucosidase gene are common in the Dutch patient population: IVS1(-13T-->G), 525delT and delexon18. 63% of Dutch GSD II patients carry one or two of these mutations, and the genotype-phenotype correlation is known. To determine the frequency of GSD II, we have screened an unselected sample of neonates for the occurrence of these three mutations. Based on the calculated carrier frequencies, the predicted frequency of the disease is 1 in 40000 divided by 1 in 138 000 for infantile GSD II and 1 in 57 000 for adult GSD II. This is about two to four times higher than previously suggested, which is a reason to become more familiar with the presentation of GSD II in its different clinical forms and to adjust the risk assessment for genetic counselling.
Similar articles
-
Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.Neurology. 2007 Jan 9;68(2):110-5. doi: 10.1212/01.wnl.0000252798.25690.76. Neurology. 2007. PMID: 17210890
-
Glycogen-storage disease type II (acid maltase deficiency): identification of a novel small deletion (delCC482+483) in French patients.Biochem Biophys Res Commun. 1997 Jun 9;235(1):138-41. doi: 10.1006/bbrc.1997.6749. Biochem Biophys Res Commun. 1997. PMID: 9196050
-
Two extremes of the clinical spectrum of glycogen storage disease type II in one family: a matter of genotype.Hum Mutat. 1997;9(1):17-22. doi: 10.1002/(SICI)1098-1004(1997)9:1<17::AID-HUMU3>3.0.CO;2-M. Hum Mutat. 1997. PMID: 8990003
-
The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.Dan Med Bull. 2002 Nov;49(4):318-45. Dan Med Bull. 2002. PMID: 12553167 Review.
-
Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature.J Neurol. 2014 Jan;261(1):83-97. doi: 10.1007/s00415-013-7137-2. Epub 2013 Oct 25. J Neurol. 2014. PMID: 24158270 Review.
Cited by
-
Immune Modulation Therapy in a CRIM-Positive and IgG Antibody-Positive Infant with Pompe Disease Treated with Alglucosidase Alfa: A Case Report.JIMD Rep. 2012;2:11-5. doi: 10.1007/8904_2011_34. Epub 2011 Sep 6. JIMD Rep. 2012. PMID: 23430847 Free PMC article.
-
Benefit of 5 years of enzyme replacement therapy in advanced late onset Pompe. A case report of misdiagnosis for three decades with acute respiratory failure at presentation.Mol Genet Metab Rep. 2022 Jul 18;32:100896. doi: 10.1016/j.ymgmr.2022.100896. eCollection 2022 Sep. Mol Genet Metab Rep. 2022. PMID: 36046397 Free PMC article.
-
Novel Mutations Found in Individuals with Adult-Onset Pompe Disease.Genes (Basel). 2020 Jan 28;11(2):135. doi: 10.3390/genes11020135. Genes (Basel). 2020. PMID: 32012848 Free PMC article.
-
Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group.BMC Neurol. 2015 Oct 15;15:205. doi: 10.1186/s12883-015-0412-3. BMC Neurol. 2015. PMID: 26471939 Free PMC article.
-
Enzyme replacement therapy and immunotherapy lead to significant functional improvement in two children with Pompe disease: a case report.J Med Case Rep. 2024 Jul 18;18(1):328. doi: 10.1186/s13256-024-04638-5. J Med Case Rep. 2024. PMID: 39020349 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources